Natera Inc. (NASDAQ:NTRA) shares rose slightly in premarket trading after a Delaware court awarded the company a 30% ongoing royalty on post-injunction revenues tied to its MRD-related patents.
The April 6, 2026 ruling builds on a prior jury award of a 20.5% royalty on pre-injunction sales, which remains unchanged. The court also upheld patent validity and infringement findings involving ArcherDx and Invitae.
Natera said the decision reinforces the strength of its MRD patent portfolio, part of its broader base of more than 650 issued or pending patents.
Technical Analysis
At $212.00, the stock is trading 7.1% above its 20-day simple moving average (SMA) of $198.02, suggesting a positive short-term trend. However, it is also trading 4.0% below its 100-day SMA of $219.58, indicating some intermediate-term weakness that traders should monitor.
The relative strength index (RSI) currently sits at 56.03, suggesting neutral momentum, while the moving average convergence divergence (MACD) indicates bullish sentiment, with the MACD line at 0.0940 above the signal line of -2.5301. This combination suggests that while the stock is not overbought, there is potential for upward movement.
- Key Resistance: $220.00 — A level where selling pressure may emerge.
- Key Support: $200.00 — A potential area of demand for buyers.
The stock has shown a robust 12-month performance of 38.73%, reflecting strong investor interest and a positive trend over the past year. Currently, the price is near the midpoint of its 52-week range, which suggests a balanced position within its historical trading range.
Earnings & Analyst Outlook
Natera is slated to provide its next financial update on May 7, 2026 (estimated).
- EPS Estimate: Loss of 56 cents (Up from Loss of 50 cents YoY)
- Revenue Estimate: $616.65 million (Up from $501.83 million YoY)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $248.06. Recent analyst moves include:
- Morgan Stanley: Overweight (Lowers Target to $250.00) (March 3)
- Wells Fargo: Equal-Weight (Raises Target to $215.00) (Feb. 27)
- Evercore ISI Group: Outperform (Raises Target to $260.00) (Feb. 27)
Benzinga Edge Rankings
Below is the Benzinga Edge scorecard for Natera, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Strong (Score: 66.45) — Stock is outperforming the broader market.
The Verdict: Natera’s Benzinga Edge signal reveals a momentum-driven story, indicating that the stock is currently in a favorable position relative to market trends.
Top ETF Exposure
- ARK Genomic Revolution ETF (BATS:ARKG): 4.10% Weight
- VanEck Biotech ETF (NASDAQ:BBH): 4.28% Weight
- Invesco Dorsey Wright Healthcare Momentum ETF (NASDAQ:PTH): 3.09% Weight
Significance: Because NTRA carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
Price Action
NTRA Stock Price Activity: Natera shares were up 0.55% at $212.00 during premarket trading on Thursday, according to Benzinga Pro data.
Photo by Michael Vi via Shutterstock
Recent Comments